Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage - Economic evaluation of a phase III clinical trial in Europe and Australia INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE Glick, H., Willke, R., Polsky, D., Llana, T., Alves, W. M., Kassell, N., Schulman, K. 1998; 14 (1): 145–60

Abstract

This study used data from a multinational phase III randomized, double-blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.

View details for DOI 10.1017/S026646230001059X

View details for Web of Science ID 000072188000013

View details for PubMedID 9509802